Histone deacetylases and cancer: causes and therapies

The language of covalent histone modifications

Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679 · see citing works

Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.

Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,856 · see citing works

Histone Acetyltransferases

Dent, S., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,844 · see citing works

Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome

Kornberg, R. D., & Lorch, Y. (1999) · Cell · doi:10.1016/s0092-8674(00)81958-3 · Cited by 1,833 · see citing works

Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen

Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · see citing works

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714 · see citing works

Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins

Frye, R. A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3000 · Cited by 1,409 · see citing works

Hemoglobin Synthesis in Murine Virus-Induced Leukemic Cells In Vitro: Stimulation of Erythroid Differentiation by Dimethyl Sulfoxide

Friend, C., Scher, W., Holland, J. G., & Satô, T. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.2.378 · Cited by 1,352 · see citing works

Acetylation: a regulatory modification to rival phosphorylation?

Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1176 · Cited by 1,155 · see citing works

Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells

Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,152 · see citing works

p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage.Preprint

Macleod, K. F., Sherry, N., Hannon, G. J., Beach, D., Tokino, T., Kinzler, K. W., Vogelstein, B., & Jacks, T. (1995) · Genes & Development · doi:10.1101/gad.9.8.935 · Cited by 1,119 · see citing works

Histone deacetylase inhibitor selectively induces p21 ^WAF1 expression and gene-associated histone acetylation

Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090 · see citing works

The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases

Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., Pillus, L., & Sternglanz, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110148297 · Cited by 970 · see citing works

DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters

Robertson, K. D., Ait-Si-Ali, S., Yokochi, T., Wade, P. A., Jones, P. L., & Wolffe, A. P. (2000) · Nature Genetics · doi:10.1038/77124 · Cited by 942 · see citing works

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases

Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914 · see citing works

The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein

Borrow, J., Stanton, V. P., Andresen, J. M., Becher, R., Behm, F. G., Chaganti, R. S. K., Civin, C. I., Distèche, C. M., Dubé, I. D., Frischauf, A. M., et al. (1996) · Nature Genetics · doi:10.1038/ng0996-33 · Cited by 766 · see citing works

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 732 · see citing works

Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12

Ito, K., Barnes, P. J., & Adcock, I. M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.18.6891-6903.2000 · Cited by 723 · see citing works

Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function

Yoshida, M., Horinouchi, S., & Beppu, T. (1995) · BioEssays · doi:10.1002/bies.950170510 · Cited by 715 · see citing works

Erythroleukemic Differentiation

Marks, P. A., & Rifkind, R. A. (1978) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.47.070178.002223 · Cited by 697 · see citing works

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 696 · see citing works

The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.

(1996) · Europe PMC (PubMed Central) · Cited by 659 · see citing works

Histone deacetylases, transcriptional control, and cancer

Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1 · Cited by 619 · see citing works

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 613 · see citing works

Mutations truncating the EP300 acetylase in human cancers

Gayther, S. A., Batley, S. J., Linger, L., Bannister, A. J., Thorpe, K. L., Chin, S., Daigo, Y., Russell, P. A., Wilson, A., Sowter, H., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 587 · see citing works

Regulation of Skeletal Myogenesis by Association of the MEF2 Transcription Factor with Class II Histone Deacetylases

Lu, J., McKinsey, T. A., Zhang, C., & Olson, E. N. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00025-3 · Cited by 547 · see citing works

The Human Histone Deacetylase Family

Gray, S. G., & Ekström, T. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5080 · Cited by 544 · see citing works

Histone deacetylase inhibitors as new cancer drugs

Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531 · see citing works

Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.

Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 516 · see citing works

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S., & Liu, J. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10860 · Cited by 511 · see citing works

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502 · see citing works

FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor

Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 484 · see citing works

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

Richon, V. M., Webb, Y., Merger, R., Sheppard, T. L., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., & Marks, P. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5705 · Cited by 420 · see citing works

Genomewide studies of histone deacetylase function in yeast

Bernstein, B., Tong, J. K., & Schreiber, S. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250477697 · Cited by 419 · see citing works

Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin

Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412 · see citing works

Conjunction dysfunction: CBP/p300 in human disease

Giles, R. H., Peters, D. J. M., & Breuning, M. H. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01438-3 · Cited by 408 · see citing works

Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects

Sambucetti, L. C., Fischer, D. D., Zabludoff, S., Kwon, P. O., Chamberlin, H., Trogani, N., Xu, H. W., & Cohen, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34940 · Cited by 390 · see citing works

A new group of potent inducers of differentiation in murine erythroleukemia cells.

Reuben, R. C., Wife, R. L., Breslow, R., et al. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.3.862 · Cited by 377 · see citing works

Functional significance of histone deacetylase diversity

Khochbin, S., Verdel, A., Lemercier, C., & Seigneurin-Berny, D. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00174-x · Cited by 366 · see citing works

Histone acetylation and disease

Timmermann, S., Lehrmann, H., Polesskaya, A., & Harel‐Bellan, A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000896 · Cited by 341 · see citing works

Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives

Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., & Nakanishi, O. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980565u · Cited by 294 · see citing works

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203176 · Cited by 285 · see citing works

Histone Acetylation and Chromatin Remodeling

Gregory, P. D., Wagner, K., & Hörz, W. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5187 · Cited by 274 · see citing works

Cloning and characterization of a histone deacetylase, HDAC9

Zhou, X., Marks, P. A., Rifkind, R. A., & Richon, V. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191375098 · Cited by 245 · see citing works

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

Kim, Y. B., Lee, K.-H., Sugita, K., Yoshida, M., & Horinouchi, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202564 · Cited by 232 · see citing works

The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression

Dhordain, P., Quief, S., Lantoine, D., Kerckaert, J., Albagli, O., Lin, R. J., & Evans, R. M. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.20.4645 · Cited by 227 · see citing works

All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders.

Rowley, J. D., Reshmi, S. C., Sobulo, O. M., Musvee, T., Anastasi, J., Raimondi, S. C., Schneider, N. R., Barredo, J. C., Cantú, E. S., Schlegelberger, B., et al. (1997) · PubMed · doi:10.1182/blood.v90.2.535 · Cited by 215 · see citing works

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

Gilbert, J., Baker, S. D., Bowling, M. K., et al. (2001) · PubMed · Cited by 209 · see citing works

Histone Acetylation at Promoters Is Differentially Affected by Specific Activators and Repressors

Deckert, J., & Struhl, K. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.8.2726-2735.2001 · Cited by 206 · see citing works

Covalent modifications of histones: expression from chromatin templates

Davie, J. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80138-x · Cited by 201 · see citing works

Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase

Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3356 · Cited by 197 · see citing works

Untitled work

(1999) · PubMed · Cited by 194 · see citing works

Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase

Kao, H.-Y., Lee, C.-H., Komarov, A., Han, C. C., & Evans, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108931200 · Cited by 193 · see citing works

A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library.

Su, G. H., Sohn, T. A., Ryu, B., & Kern, S. E. (2000) · PubMed · Cited by 189 · see citing works

Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease

Mahlknecht, U., & Hoelzer, D. F. (2000) · Molecular Medicine · doi:10.1007/bf03402044 · Cited by 178 · see citing works

Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment

Huang, L., & Pardee, A. B. (2000) · Molecular Medicine · doi:10.1007/bf03401823 · Cited by 164 · see citing works

Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome

Murata, T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1071 · Cited by 163 · see citing works

The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.

Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2001) · PubMed · Cited by 155 · see citing works

Telomerase activation by histone deacetylase inhibitor in normal cells

Takakura, M. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.14.3006 · Cited by 154 · see citing works

Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.

Komatsu, Y., Tomizaki, K., Tsukamoto, M., Kato, T., Nishino, N., Sato, S., Yamori, T., Tsuruo, T., Furumai, R., Yoshida, M., et al. (2001) · PubMed · Cited by 145 · see citing works

Transcription therapy for cancer

Pandolfi, P. P. (2001) · Oncogene · doi:10.1038/sj.onc.1204299 · Cited by 145 · see citing works

Acute Mixed Lineage Leukemia With an inv(8)(p11q13) Resulting in Fusion of the Genes for MOZ and TIF2

Liang, J., Prouty, L. A., Williams, B. J., Dayton, M. A., & Blanchard, K. L. (1998) · Blood · doi:10.1182/blood.v92.6.2118 · Cited by 141 · see citing works

Chronic Oral Administration of CI-994: A Phase I Study

Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L. E., Zalupski, M. M., Radulovic, L. L., Valdivieso, M., & LoRusso, P. M. (2001) · Investigational New Drugs · doi:10.1023/a:1006489328324 · Cited by 136 · see citing works

Butyrate as a differentiating agent: pharmacokinetics, analogues and current status

Newmark, H. L., Lupton, J. R., & Young, C. W. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90023-x · Cited by 130 · see citing works

Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras

Zhou, X., Richon, V. M., Wang, A. H., Yang, X., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250494697 · Cited by 123 · see citing works

Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.

Butler, L. M., Webb, Y., Agus, D. B., et al. (2001) · PubMed · Cited by 121 · see citing works

Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate

Qiu, L., Kelso, M. J., Hansen, C. P., West, M. L., Fairlie, D. P., & Parsons, P. G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690493 · Cited by 114 · see citing works

Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).

Cohen, L. A., Amin, S., Marks, P. A., Rifkind, R. A., Desai, D. H., & Richon, V. M. (1999) · PubMed · Cited by 112 · see citing works

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

Gore, S. D., & Carducci, M. A. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.12.2923 · Cited by 109 · see citing works

Epigenetic Regulation of Gelsolin Expression in Human Breast Cancer Cells

Mielnicki, L. M., Ying, A., Head, K. L., Asch, H. L., & Asch, B. B. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4461 · Cited by 106 · see citing works

Histone Deacetylase: A Target for Antiproliferative and Antiprotozoal Agents

Meinke, P. T., & Liberator, P. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373787 · Cited by 103 · see citing works

Analogues of trichosтatin a and trapoxin B as histone deacetylase inhibitors

Jung, M., Hoffmann, K., Brosch, G., & Loidl, P. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)00284-9 · Cited by 91 · see citing works

Yeast HOS3 forms a novel trichostatin A-insensitive homodimer with intrinsic histone deacetylase activity

Carmen, A. A., Griffin, P. R., Calaycay, J. R., Rundlett, S. E., Suka, Y., & Grunstein, M. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12356 · Cited by 87 · see citing works

The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin

Murray, P. J., Kranz, M., Ladlow, M., Taylor, S., Berst, F., Holmes, A. B., Keavey, K., Jaxa‐Chamiec, A. A., Seale, P. W., Stead, P., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00049-x · Cited by 76 · see citing works

HDAC1, a Histone Deacetylase, Forms a Complex with Hus1 and Rad9, Two G2/M Checkpoint Rad Proteins

Cai, R. L., Yan‐Neale, Y., Cueto, M. A., Xu, H. W., & Cohen, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000168200 · Cited by 74 · see citing works

Histone Hyperacetylation Induced by Histone Deacetylase Inhibitors Is Not Sufficient to Cause Growth Inhibition in Human Dermal Fibroblasts

Brinkmann, H., Dahler, A. L., Popa, C., Serewko-Auret, M. M., Parsons, P. G., Gabrielli, B. G., Burgess, A., & Saunders, N. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100206200 · Cited by 68 · see citing works

Design and synthesis of a novel class of histone deacetylase inhibitors

Lavoie, R., Bouchain, G., Fréchette, S., Woo, S. H., Khalil, E. A., Leit, S. M., Fournel, M., Yan, P. T., Trachy-Bourget, M.-C., Beaulieu, C., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00552-2 · Cited by 67 · see citing works

Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis.

Allfrey, V. G. (1966) · PubMed · Cited by 56 · see citing works

Synthesis of Apicidin-Derived Quinolone Derivatives: Parasite-Selective Histone Deacetylase Inhibitors and Antiproliferative Agents

Meinke, P. T., Colletti, S. L., Doss, G. A., Myers, R. W., Gurnett, A. M., Dulski, P. M., Darkin‐Rattray, S. J., Allocco, J., Galuska, S., Schmatz, D. M., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0001976 · Cited by 50 · see citing works

In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi‐scid/scid Mice

Kosugi, H., Ito, M., Yamamoto, Y., Towatari, M., Ito, M., Ueda, R., Saito, H., & Naoe, T. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01126.x · Cited by 46 · see citing works

Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma

Sakai, K., Nagahara, H., Abe, K., et al. (1992) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1992.tb00982.x · Cited by 44 · see citing works

Association of Histone Deacetylase with COUP-TF in Tumorigenic Ad12-Transformed Cells and Its Potential Role in Shut-Off of MHC Class I Transcription

Smirnov, D. A., Hou, S., & Ricciardi, R. P. (2000) · Virology · doi:10.1006/viro.1999.0181 · Cited by 43 · see citing works

Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells

Parsons, P. G., Hansen, C. P., Fairlie, D. P., et al. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00016-6 · Cited by 39 · see citing works

Chromatin organisation and human disease

Urnov, F. D., & Wolffe, A. P. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.5.665 · Cited by 24 · see citing works

UV inducibility of rat proliferating cell nuclear antigen gene promoter

Chang, H., Lai, Y., Cheng, C., Ho, J., Ding, S., & Liu, Y. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990601)73:3 · Cited by 21 · see citing works

Linkages of nuclear architecture to biological and pathological control of gene expression

Stein, G. S., van Wijnen, A. J., Stein, J. L., Lian, J. B., Pockwinse, S. M., & McNeil, S. M. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1998)72:30/31+ · Cited by 6 · see citing works

Histone deacetylases (HDACs): characterization of the classical HDAC family

RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114 · see citing works

Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase

Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750 · see citing works

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312 · see citing works

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · see citing works

The growing landscape of lysine acetylation links metabolism and cell signalling

Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., & Mann, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3841 · Cited by 1,324 · see citing works

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · see citing works

Anti-inflammatory Agents: Present and Future

Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095 · see citing works

Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis

Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025 · see citing works

Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1

Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205670200 · Cited by 1,002 · see citing works

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755 · see citing works

HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo

Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · see citing works

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713 · see citing works

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575 · see citing works

RAR and RXR modulation in cancer and metabolic disease

Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517 · see citing works

Epigenetics and cancer

Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489 · see citing works

Differentiation therapy revisited

de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462 · see citing works

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429 · see citing works

Histone deacetylase 8 in neuroblastoma tumorigenesis

Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398 · see citing works

Microglia: Agents of the CNS Pro-Inflammatory Response

Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365 · see citing works

Vitamin D and the epigenome

Fetahu, I. S., Höbaus, J., & Kállay, E. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00164 · Cited by 313 · see citing works

Formation and signaling actions of electrophilic lipids

Schopfer, F. J., Cipollina, C., & Freeman, B. A. (2011) · Chemical Reviews · doi:10.1021/cr200131e · Cited by 299 · see citing works

Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides

Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.091 · Cited by 261 · see citing works

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2510 · Cited by 237 · see citing works

Top‐down proteomics in health and disease: Challenges and opportunities

Gregorich, Z. R., & Ge, Y. (2014) · PROTEOMICS · doi:10.1002/pmic.201300432 · Cited by 217 · see citing works

Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective

Kumar, V., Kundu, S., Singh, A., & Singh, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666210609160017 · Cited by 210 · see citing works

research paper: Differential expression of <i>HDAC3, HDAC7</i> and <i>HDAC9</i> is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208 · see citing works

Protein neddylation and its role in health and diseases

Zhang, S., Yu, Q., Li, Z., Zhao, Y., & Sun, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01800-9 · Cited by 171 · see citing works

Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors

Whitehead, L., Dobler, M. R., Radetich, B., Zhu, Y., Atadja, P. W., Claiborne, T., Grob, J. E., McRiner, A., Pancost, M. R., Patnaik, A., et al. (2011) · Bioorganic &amp; Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.030 · Cited by 164 · see citing works

Assembly of the SMRT–histone deacetylase 3 repression complex requires the TCP-1 ring complex

Guenther, M. G., Yu, J., Kao, G. D., Yen, T. J., & Lazar, M. A. (2002) · Genes &amp; Development · doi:10.1101/gad.1037502 · Cited by 138 · see citing works

Lysine Deacetylases Hda1 and Rpd3 Regulate Hsp90 Function thereby Governing Fungal Drug Resistance

Robbins, N., Leach, M. D., & Cowen, L. E. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.035 · Cited by 126 · see citing works

Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4

Sailaja, B. S., Cohen-Carmon, D., Zimmerman, G., Soreq, H., & Meshorer, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209990110 · Cited by 121 · see citing works

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

LaBonte, M. J., Wilson, P. M., Fazzone, W., Groshen, S., Lenz, H.-J., & Ladner, R. D. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-67 · Cited by 99 · see citing works

Chemical Genetic Modifier Screens

Koeller, K. M., Haggarty, S. J., Perkins, B. D., Leykin, I., Wong, J. C., Kao, M.-C. J., & Schreiber, S. L. (2003) · Chemistry &amp; Biology · doi:10.1016/s1074-5521(03)00093-0 · Cited by 89 · see citing works

Histone deacetylase inhibitors may reduce pathogenicity and virulence in<i>Candida albicans</i>

Simonetti, G., Passariello, C., Rotili, D., Mai, A., Garaci, E., & Palamara, A. T. (2007) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2007.00276.x · Cited by 57 · see citing works

Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens

Nicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48 · see citing works

HDAC inhibition ameliorates cone survival in retinitis pigmentosa mice

Samardzija, M., Corna, A., Gomez-Sintes, R., Jarboui, M. A., Armento, A., Roger, J. E., Petridou, E., Haq, W., Paquet-Durand, F., Zrenner, E., et al. (2021) · Cell Death &amp; Differentiation · doi:10.1038/s41418-020-00653-3 · Cited by 48 · see citing works

An epigenetically altered tumor cell vaccine

Khan, A. N., Magner, W., & Tomasi, T. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0513-0 · Cited by 42 · see citing works

Engaging plasticity: Differentiation therapy in solid tumors

Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35 · see citing works

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment

Lehmann, M., Hoffmann, M. J., Koch, A., Ulrich, S. M., Schulz, W. A., & Niegisch, G. (2014) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-014-0059-8 · Cited by 34 · see citing works

Vorinostat attenuates UVB-induced skin senescence by modulating NF-κB and mTOR signaling pathways

Dai, Q., Wang, Z., Wang, X., Lian, W., Ge, Y., Song, S., Li, F., Zhao, B., Li, L., Wang, X., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-95624-4 · Cited by 17 · see citing works

Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer

Meteran, H., Knudsen, A. Ø., Jørgensen, T. L., Nielsen, D., & Herrstedt, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030897 · Cited by 12 · see citing works

Proteomic study identified HSP 70kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms

Fujii, K., Suzuki, N., Ikeda, K., Hamada, T., Yamamoto, T., Kondo, T., & Iwatsuki, K. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2011.11.010 · Cited by 10 · see citing works

Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook

Lv, L.-Z., Wang, Z.-D., Ren, J.-J., Li, L.-H., Liu, X.-B., Li, J.-L., Zhu, H., Jiang, B., Han, Y.-P., Zhou, X.-M., et al. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2025.1722453 · Cited by 7 · see citing works

A Sensitive and Flexible Assay for Determining Histone Deacetylase 1 (HDAC1) Activity

Wu, M.-Y., & Wu, R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3667-0_1 · Cited by 1 · see citing works

Advances in pharmacological study of histone deacetylase inhibitors

Na, L. (2004) · Chinese New Drugs Journal

Histone deacetylase inhibitors: discovery and development as anticancer agents

Marks, P. A., & Dokmanovic, M. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.12.1497 · Cited by 318 · see citing works

[The mechanism underlying histone deacetylases regulating cardiac hypertrophy].

Ren, L., Wu, X. S., & Li, Y. Q. (2020) · PubMed · doi:10.16288/j.yczz.19-346

HISTONE DEACETYLASES: TRANSCRIPTIONAL REGULATION AND OTHER CELLULAR FUNCTIONS

Verdin, E. M. (2006) · doi:10.1385/1597450243 · Cited by 22 · see citing works